ArticleEuropean archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery2025
Postoperative adjuvant immunotherapy versus standard of care in resectable locally advanced head and neck squamous cell carcinoma with intermediate- and high-risk factors: a real-world retrospective study.
Article in European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
purposeImproving the prognosis of patients with locally advanced head and neck squamous cell carcinoma (LA-HNSCC) who have intermediate- and high-risk factors has long been a priority for head and neck surgeons. This study aims to evaluate programmed death-1 (PD-1) inhibitors administered as maintenance monotherapy after standard of care in patients with postoperative intermediate- and high-risk LA-HNSCC.
methodsWe retrospectively reviewed 47 postoperative intermediate- and high-risk patients with LA-HNSCC who underwent operative interventions between 2016 and 2022. These patients were divided into two groups: a standard therapy group (n = 24) and an adjuvant immunotherapy group (n = 23 standard therapy + immunotherapy). The primary endpoint was 2-year progression-free survival (PFS) and 2-year overall survival (OS). Stratification analysis according to baseline combined positivity score (CPS), with cutoffs set at CPS ≥ 20, was performed to analyze the correlation between CPS and treatment outcomes.
resultsThe 2-year PFS and OS rates in the adjuvant immunotherapy group were 82.6% and 96.0%, respectively, compared to 62.5% (χ2 = 2.376, P = 0.123) and 75.0% (χ2 = 3.646, P = 0.056) in the standard therapy group. Stratified analysis showed that the 2-year PFS and OS rates for patients in the adjuvant immunotherapy group with programmed death ligand 1 (PD-L1) combined positive score (CPS) ≥ 20 significantly improved compared to the standard therapy group (93.3% vs. 62.5%, χ2 = 4.573, P = 0.033), (100.0% vs. 75.0%, χ2 = 4.212, P = 0.040).
conclusionThis cohort study found that adjuvant immunotherapy after the standard of care improved PFS and OS in patients with postoperative intermediate- and high-risk LA-HNSCC, especially for those with a PD-L1 CPS of 20 or more.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.